Quantum BioPharma Ltd. (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness Inc., has appointed Michael “Zappy” Zapolin as chief executive officer. Zapolin’s mandate includes financing and listing Unbuzzd on a stock exchange, followed by a nationwide commercial marketing and product rollout in the United States, according to the announcement disseminated on behalf of Quantum BioPharma Ltd.. Former CEO Richard Buzbuzian is assisting with the transition to a publicly listed company, which is scheduled to go effective in the next quarter.
Unbuzzd markets unbuzzd™, a beverage designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms. The company said the product is backed by a peer-reviewed clinical study and is currently available through Amazon and its website. The appointment of Zapolin, a well-known entrepreneur and investor, signals a strategic push to scale the brand commercially and access public capital markets.
For Quantum BioPharma, the move is significant because the company invented UNBUZZD™ and spun out its over-the-counter version to Unbuzzd Wellness Inc., formerly Celly Nutrition Corp. Quantum retains ownership of 19.84% of Unbuzzd as of March 31, 2026. The agreement with Unbuzzd includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once that threshold is reached, the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
This structure could provide Quantum with a long-term revenue stream tied to Unbuzzd’s commercial success while preserving its ability to pursue pharmaceutical applications. The royalty terms align Quantum’s interests with Unbuzzd’s growth, and the potential public listing could enhance Unbuzzd’s access to capital for marketing and expansion. For readers and investors, the news highlights how biopharmaceutical companies are increasingly spinning out consumer-facing products to monetize intellectual property while focusing on core drug development.
Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. The full press release can be viewed at https://ibn.fm/CBNq1.
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; article and editorial syndication to 5,000+ outlets; enhanced press release enhancement to ensure maximum impact; social media distribution via IBN to millions of social media followers; and a full array of tailored corporate communications solutions.
